Post-Exercise Recovery Optimization

1 Jammes2020 — Altered Muscle Membrane Potential in ME/CFS

Full Citation:: Jammes Y, Adjriou N, Kipson N, et al. Altered muscle membrane potential and redox status differentiates two subgroups of patients with chronic fatigue syndrome. J Transl Med. 2020;18(1):173. DOI:: 10.1186/s12967-020-02341-9 PMID:: 32306967 PMCID:: PMC7168976 Study Design:: Cross-sectional exercise physiology study with M-wave recordings Sample Size:: 72 ME/CFS patients (no healthy controls) Key Findings::

- 39/72 (54%) had altered muscle membrane excitability (M-wave changes) + elevated oxidative stress (TBARS, ORP)
- 33/72 (46%) had normal muscle membrane and lower baseline oxidative stress
- M-wave changes inversely proportional to TBARS and ORP
- Two subgroups identified, suggesting differential recovery needs
- Resting muscles already show membrane excitability alterations

Conclusion:: Muscle membrane dysfunction and oxidative stress distinguish ME/CFS subgroups. Oxidative stress biomarkers may improve diagnosis and subgroup stratification. Limitations:: Single-center; no healthy controls; 10-min recovery window insufficient for PEM; subgroup distinction not independently replicated. Certainty:: 0.60

2 Munemoto2017 — Waon rCBF SPECT Imaging

Full Citation:: Munemoto T, Soejima Y, Masuda A, et al. Increase in the Regional Cerebral Blood Flow following Waon Therapy in Patients with Chronic Fatigue Syndrome: A Pilot Study. Intern Med. 2017;56(14):1817–1823. DOI:: 10.2169/internalmedicine.56.8001 PMID:: 28717076 Study Design:: Open-label pilot; SPECT imaging before/after intervention Sample Size:: 12 CFS patients Key Findings::

- Waon therapy (far-infrared sauna 60°C, 15 min, 5×/week for 5 weeks)
- rCBF significantly increased in bilateral prefrontal cortex, anterior cingulate gyrus, and thalamus post-treatment
- rCBF increase correlated with reduced fatigue scores

Conclusion:: Cerebral hypoperfusion as a therapeutic target; Waon therapy may reduce fatigue through rCBF enhancement. Limitations:: n=12; no control group; open-label; same group as Soejima2015 (overlapping sample possible). Certainty:: 0.30

3 Li2024 — Massage Meta-Analysis for CFS

Full Citation:: Li J, Piao F, Zeng Q, et al. The effect of massage on patients with chronic fatigue syndrome: A systematic review and meta-analysis. Medicine (Baltimore). 2024;103(18):e37973. DOI:: 10.1097/MD.0000000000037973 PMID:: 38701244 Study Design:: Systematic review and meta-analysis of RCTs Sample Size:: 5 RCTs, 385 total patients Key Findings::

- Massage significantly reduced fatigue (SMD = -0.89, 95% CI -1.57 to -0.21, p=0.01)
- Improved quality of life, anxiety, and depression
- Various massage types (Tui Na, acupressure, Swedish)

Conclusion:: Massage therapy may effectively alleviate fatigue in CFS, but evidence quality is limited by heterogeneity and small study numbers. Limitations:: Few studies; high heterogeneity; most from China; varied protocols; publication bias possible. Certainty:: 0.45

4 White2023 — Pro-GET NICE Critique

Full Citation:: White PD, Abbey S, Angus B, et al. Anomalies in the review process and interpretation of the evidence in the NICE guideline for chronic fatigue syndrome and myalgic encephalomyelitis. J Neurol Neurosurg Psychiatry. 2023;94(9):745–752. DOI:: 10.1136/jnnp-2022-330463 PMID:: 37434321 Study Design:: Evidence critique / position paper Key Findings::

- 51 authors argue NICE 2021 guideline misrepresented GET evidence
- GET showed moderate benefit in multiple RCTs including PACE trial
- Claim harms not consistently demonstrated in trials
- Cite 7 "anomalies" in NICE review process and evidence interpretation

Conclusion:: Authors argue GET should remain an option for some ME/CFS patients, contrary to NICE 2021 recommendation. Limitations:: Authors include PACE trial investigators (COI); patient groups strongly oppose GET; PACE methodology criticized (subjective outcomes, lowered recovery thresholds). Certainty:: 0.40

5 Vink2025 — Anti-GET PACE Analysis

Full Citation:: Vink M, Partyka-Vink K. The PACE Trial’s GET Manual for Therapists Exposes the Fixed Incremental Nature of Graded Exercise Therapy for ME/CFS. Life (Basel). 2025;15(4):584. DOI:: 10.3390/life15040584 PMID:: 40283139 Study Design:: Analysis of original PACE GET therapist manual Key Findings::

- GET manual specifies fixed incremental increases in exercise duration regardless of symptoms
- Fixed incremental approach conflicts with "energy envelope" pacing
- Supports NICE 2021 decision to recommend against GET
- Concludes harms reported by patients are consistent with manual design

Conclusion:: GET’s fixed incremental structure is incompatible with post-exertional nature of ME/CFS and likely harmful. Limitations:: Single-study analysis; author COI as patient advocate/critic of PACE; lower-tier journal. Certainty:: 0.30

6 Godlewska2024 — Creatine ME/CFS Feasibility

Full Citation:: Godlewska BR, Sylvester A, Emir U, et al. Six-Week Supplementation with Creatine in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): A Magnetic Resonance Spectroscopy Feasibility Study at 3 Tesla. Nutrients. 2024;16(19):3308. DOI:: 10.3390/nu16193308 PMID:: 39408275 Study Design:: Open-label feasibility study with MRS at 3T Sample Size:: 14 ME/CFS patients Key Findings::

- 6-week creatine monohydrate (20g/day × 5d loading, then 10g/day)
- No significant changes in brain PCr, ATP, or pH on 3T MRS
- Self-reported fatigue trended toward improvement (not significant)
- Feasibility established: protocol acceptable, 3T MRS feasible

Conclusion:: Creatine supplementation did not significantly alter brain energetics or fatigue in this small feasibility study. Larger placebo-controlled trials needed. Limitations:: n=14; no placebo; open-label; short duration (6 weeks); brain MRS may miss muscle PCr changes; trend may be placebo. Certainty:: 0.30

7 Lien2019 — Abnormal Lactate in ME/CFS CPET

Full Citation:: Lien K, Johansen B, Veierød MB, et al. Abnormal blood lactate accumulation during repeated exercise testing in myalgic encephalomyelitis/chronic fatigue syndrome. Physiol Rep. 2019;7(18):e14138. DOI:: 10.14814/phy2.14138 PMID:: 31161646 Study Design:: Case-control repeated CPET on consecutive days Sample Size:: 18 ME/CFS patients, 18 matched controls Key Findings::

- ME/CFS patients had higher blood lactate at submaximal workloads vs controls on day 1
- Day 2: abnormal lactate accumulation at even lower workloads in ME/CFS
- Controls showed normal lactate handling on both days
- Impaired metabolic recovery capacity between exercise sessions

Conclusion:: Repeated exercise reveals impaired lactate metabolism in ME/CFS, indicating reduced recovery capacity between exercise sessions. Two-day CPET is essential to detect this abnormality. Limitations:: n=18 moderate sample; well-designed (matched controls, 2-day CPET). Certainty:: 0.55

8 Magarinos2013 — Mast Cell Tryptases Activate MMP-3 and MMP-13 in Cartilage

Full Citation:: Magarinos NJ, Bryant KJ, Fosang AJ, Adachi R, Stevens RL, McNeil HP. Mast cell-restricted, tetramer-forming tryptases induce aggrecanolysis in articular cartilage by activating matrix metalloproteinase-3 and -13 zymogens. Journal of Immunology. 2013;191(3):1404-1412. (Magarinos et al. 2013) DOI:: 10.4049/jimmunol.1300856 PMID:: 23797671 Key Findings::

- mMCP-6-null mice lost less aggrecan from articular cartilage ECM during inflammatory arthritis
- Recombinant hTryptase-β (human ortholog) and mMCP-6 activated MMP-3 and MMP-13 zymogens in cartilage explants
- Aggrecan fragments contained DIPEN and FFGVG neoepitopes — consistent with MMP-dependent cleavage
- hTryptase-β unable to induce aggrecanolysis in Chloe mice (resist MMP cleavage at DIPEN↓FFGVG site)

Conclusion:: Mast cell tryptases act upstream of MMP-3 and MMP-13 to induce aggrecan and ECM degradation in cartilage. Direct mechanistic link between mast cell degranulation and connective tissue matrix breakdown. Limitations:: Ex vivo and mouse model; direct extrapolation to human ligament/bone ECM requires confirmation; cartilage-specific (not ligament-specific). Certainty:: 0.70

9 Saarinen1994 — Mast Cell Chymase Activates Procollagenase (MMP-1)

Full Citation:: Saarinen J, Kalkkinen N, Welgus HG, Kovanen PT. Activation of human interstitial procollagenase through direct cleavage of the Leu83-Thr84 bond by mast cell chymase. Journal of Biological Chemistry. 1994;269(27):18134-18140. (Saarinen et al. 1994) PMID:: 8027075 Key Findings::

- Purified human skin chymase activates procollagenase (MMP-1) in time- and concentration-dependent manner
- Heparin accelerates cleavage rate and prevents further degradation
- Novel mechanism: direct cleavage of Leu83-Thr84 bond without intermediate species
- Distinct from all other known MMP activation mechanisms

Conclusion:: Mast cell chymase directly activates the key collagen-degrading enzyme MMP-1, establishing a direct biochemical pathway from mast cell degranulation to collagen degradation. Limitations:: In vitro study using purified proteins; context is skin, not ligament/joint; >30 years old but foundational and unreplicated in modern context. Certainty:: 0.75

11 Lind2022 — Mast Cell Chymase Negatively Impacts Osteoblasts and Bone ECM

Full Citation:: Lind T, Melo FR, Gustafson AM, Sundqvist A, Zhao XO, Moustakas A, Melhus H, Pejler G. Mast cell chymase has a negative impact on human osteoblasts. Matrix Biology. 2022;112:1-19. (Lind et al. 2022) DOI:: 10.1016/j.matbio.2022.07.005 PMID:: 35908613 Key Findings::

- Chymase directly impacts human primary osteoblasts, reducing bone matrix integrity
- Mice lacking chymase develop increased diaphyseal bone mass
- Chymase affects osteoblast function and ECM production

Conclusion:: Mast cell chymase is a negative regulator of connective tissue matrix in bone, providing further evidence that mast cell proteases degrade connective tissue. Limitations:: Bone-specific; in vitro and mouse model; not directly ligament/joint capsule. Certainty:: 0.65

12 Zhu2026 — Histaminylation Alters Collagen Matrix Mechanics

Full Citation:: Zhu J, Sun D, Zeng G, Wu K, Yang X, Zhu X, Aierken D, Ding S, Wang X, Ge J, Yang X. Histaminylation alters collagen matrix mechanics and attenuates cardiac fibrosis post-myocardial infarction via mechanotransduction signaling axis. Signal Transduction and Targeted Therapy. 2026;11(1):229. (Zhu et al. 2026) DOI:: 10.1038/s41392-026-02721-5 PMID:: 42270610 Key Findings::

- Histamine covalently modifies collagen via histaminylation (non-enzymatic post-translational modification)
- Histaminylation directly alters collagen matrix mechanical properties
- Affects mechanotransduction signaling in fibroblasts
- Novel MMP-independent mechanism for histamine-mediated ECM alteration

Conclusion:: Beyond MMP activation, mast cell-derived histamine can directly alter collagen mechanics through histaminylation. Provides a second, independent mechanism by which mast cells could weaken connective tissue. Limitations:: Cardiac fibrosis context; not yet studied in ligament/tendon/joint; mechanism novel and not yet replicated. Certainty:: 0.70

13 Guo2021 — Mast Cell Proteases and Synovial HA Degradation

Full Citation:: Guo Y, Wei T, Hu N, Zhou X. Disrupted homeostasis of synovial hyaluronic acid and its associations with synovial mast cell proteases of rheumatoid arthritis patients and collagen-induced arthritis rats. Immunologic Research. 2021;69(6):584-593. (Guo et al. 2021) DOI:: 10.1007/s12026-021-09231-2 PMID:: 34482531 Key Findings::

- Synovial mast cell proteases (tryptase, chymase) correlated with disrupted HA homeostasis
- MMP-2 and MMP-9 also associated with HA degradation in RA synovium and CIA rats
- Inflammation-induced HA rapid-metabolism reduces viscosity and ECM integrity

Conclusion:: Mast cell serine proteases contribute to ECM breakdown in joint tissues, with both direct protease activity and indirect MMP activation. Limitations:: RA context (inflammatory arthritis), not hypermobility; correlational; n=limited. Certainty:: 0.50

14 Hart2026 — Mast Cells in Intervertebral Disc and Connective Tissues

Full Citation:: Hart DA. Potential Role of Mast Cells in Intervertebral Disc Ageing, Herniation Resolution, and Degeneration: Evidence and Lessons Learned from Studies of Mast Cells in Other Connective Tissues. International Journal of Molecular Sciences. 2026;27(6):2804. (Hart 2026) DOI:: 10.3390/ijms27062804 PMID:: 41898664 Key Findings::

- Mast cells found in nucleus pulposus; numbers elevated in degenerative conditions
- Proposes mast cell stabilizers (ketotifen) as treatment for CT degeneration
- Notes MMP-3 and HTRA1 as target proteinsases in affected tissues
- Comprehensive review across CT contexts (skin, heart, bone, intervertebral disc)

Conclusion:: Mast cells play a role in CT integrity across multiple tissue types. MC stabilization (ketotifen) proposed as therapeutic strategy for preserving CT. Limitations:: Review, not original data; no direct hypermobility data; primarily IVD-focused. Certainty:: 0.55

15 Weiss2026 — Subglottic Stenosis in MCAS: Connective Tissue Pathology

Full Citation:: Weiss N, Elijah I, Dahiya R, Menton S, Ishmael L, Rutt A. Iatrogenic Subglottic Stenosis in Mast Cell Activation Syndrome: A Sentinel Case and Narrative Review. Ear, Nose, and Throat Journal. 2026. (Weiss et al. 2026) DOI:: 10.1177/01455613261423415 PMID:: 41700025 Key Findings::

- Sentinel case of grade III subglottic stenosis in MCAS patient
- Mast cell mediators implicated in airway fibrosis and impaired wound healing
- Post-operative management: cromolyn, fexofenadine, montelukast, omalizumab
- Literature review supports mechanistic role for MC mediators in CT pathology

Conclusion:: MCAS patients uniquely vulnerable to connective tissue pathology of the airway. Illustrates clinical relevance of MC → CT link. Limitations:: Single case report; airway fibrosis, not ligament laxity (opposite CT pathology). Certainty:: 0.40

16 Wilson2026 — Mast Cell Score Associates with Symptoms in hEDS/HSD (n=2141)

Full Citation:: Wilson FC, Zangerle DJ, Rozen LE, et al. Mast cell score associates with wide-spread mast cell symptoms and comorbidities in patients with hEDS and HSD. medRxiv [Preprint]. 2026. (Wilson et al. 2026) DOI:: 10.64898/2026.05.31.26354552 PMID:: 42282176 Key Findings::

- N=2141 hEDS/HSD patients; 25% had high MC score (≥5/11)
- IgE significantly elevated in high MC group (hEDS p=0.0004; HSD p=0.003)
- Random tryptase and urinary MC markers NOT elevated in high MC group
- Random IgE, tryptase and MBP elevated by ELISA in high MC group
- Abuse/PTSD nearly doubled in high MC group (p < 0.0001)

Conclusion:: Largest cohort evidence that MC symptom burden is clinically significant in hEDS/HSD. IgE elevation in MC-high subgroup suggests IgE pathway involvement. Random mediator measurement misses most cases. Limitations:: Preprint (not peer-reviewed); self-reported MC score; no longitudinal hypermobility data; random mediator collection. Certainty:: 0.45

17 Ganesh2024 — Long COVID and HSD Share Pathophysiology

Full Citation:: Ganesh R, Munipalli B. Long COVID and hypermobility spectrum disorders have shared pathophysiology. Frontiers in Neurology. 2024;15:1455498. (Ganesh and Munipalli 2024) DOI:: 10.3389/fneur.2024.1455498 PMID:: 39301475 Key Findings::

- Hypermobility detected in 30-57% of ME/CFS, fibromyalgia, POTS, and long COVID
- "Mast cell activation and degranulation occurring in both LC and ME/CFS may result in hyperinflammation and damage to connective tissue in these patients, thereby inducing hypermobility"
- Proposes screening for hypermobility in LC patients

Conclusion:: Directly proposes the mechanism that MC activation → CT damage → hypermobility. Hypothesis-level paper from Mayo Clinic. Limitations:: Hypothesis/review; no original data; does not examine MC mediators or CT biomarkers. Certainty:: 0.40

18 Martin2019 — hEDS: Acquired or Heritable?

Full Citation:: Martin A. An acquired or heritable connective tissue disorder? A review of hypermobile Ehlers Danlos Syndrome. European Journal of Medical Genetics. 2019;62(7):103672. (Martin 2019) DOI:: 10.1016/j.ejmg.2019.103672 PMID:: 31102747 Key Findings::

- No definitive molecular basis identified for most hEDS
- Questions whether hEDS is purely heritable vs. acquired musculoskeletal condition
- Current hEDS classification may encompass both heritable and acquired phenotypes

Conclusion:: The absence of a consistent genetic defect in most hEDS patients opens the door to acquired/non-genetic mechanisms (including MC-mediated CT degradation). Limitations:: Narrative review; does not specifically address mast cells; no original data. Certainty:: 0.55

19 Matheny2025 — Systematic Review: Omalizumab for Refractory MCAS

Full Citation:: Matheny MV, Craig T, Al-Shaikhly T. Systematic review of omalizumab for refractory clonal and non-clonal mast cell activation syndrome. Allergy and Asthma Proceedings. 2025;46(1):11-18. (Matheny, Craig, and Al-Shaikhly 2025) DOI:: 10.2500/aap.2025.46.240076 PMID:: 39741373 Key Findings::

- 9 studies, 28 refractory MCAS patients
- 75% nonclonal, 25% clonal MCAS
- 61% partial response, 18% complete response
- No major adverse events reported
- Higher dose (≥300 mg/month) associated with complete response

Conclusion:: Omalizumab is safe and effective for refractory MCAS. No studies have examined effects on CT integrity or hypermobility. Limitations:: Only 28 patients; no RCTs; no CT/hypermobility outcomes; short follow-up in most studies. Certainty:: 0.55

20 Berry2019 — Low-Dose Omalizumab for Idiopathic MCAS

Full Citation:: Berry R, Hollingsworth P, Lucas M. Successful treatment of idiopathic mast cell activation syndrome with low-dose Omalizumab. Clinical and Translational Immunology. 2019;8(10):e01075. (Berry, Hollingsworth, and Lucas 2019) DOI:: 10.1002/cti2.1075 PMID:: 31576204 Key Findings::

- Low-dose omalizumab 150 mg monthly → 5-year sustained clinical response
- Controlled debilitating MCAS symptoms
- Allowed reintroduction and maintenance of bee venom SCIT

Conclusion:: Low-dose omalizumab is effective for idiopathic MCAS maintenance. Safe long-term use documented. Limitations:: Single case report; idiopathic MCAS only; no CT outcomes. Certainty:: 0.40

References

Berry, R., P. Hollingsworth, and M. Lucas. 2019. “Successful Treatment of Idiopathic Mast Cell Activation Syndrome with Low-Dose Omalizumab.” Clinical and Translational Immunology 8 (10): e01075. https://doi.org/10.1002/cti2.1075.
Ganesh, Ravindra, and Bala Munipalli. 2024. “Long COVID and Hypermobility Spectrum Disorders Have Shared Pathophysiology.” Frontiers in Neurology 15: 1455498. https://doi.org/10.3389/fneur.2024.1455498.
Guo, Y., T. Wei, N. Hu, and X. Zhou. 2021. “Disrupted Homeostasis of Synovial Hyaluronic Acid and Its Associations with Synovial Mast Cell Proteases of Rheumatoid Arthritis Patients and Collagen-Induced Arthritis Rats.” Immunologic Research 69 (6): 584–93. https://doi.org/10.1007/s12026-021-09231-2.
Hart, D. A. 2026. “Potential Role of Mast Cells in Intervertebral Disc Ageing, Herniation Resolution, and Degeneration: Evidence and Lessons Learned from Studies of Mast Cells in Other Connective Tissues.” International Journal of Molecular Sciences 27 (6): 2804. https://doi.org/10.3390/ijms27062804.
Janicki, J. S., G. L. Brower, J. D. Gardner, M. F. Forman, J. A. Jr. Stewart, D. B. Murray, and A. L. Chancey. 2006. “Cardiac Mast Cell Regulation of Matrix Metalloproteinase-Related Ventricular Remodeling in Chronic Pressure or Volume Overload.” Cardiovascular Research 69 (3): 657–65. https://doi.org/10.1016/j.cardiores.2005.10.020.
Lind, T., F. R. Melo, A. M. Gustafson, A. Sundqvist, X. O. Zhao, A. Moustakas, H. Melhus, and G. Pejler. 2022. “Mast Cell Chymase Has a Negative Impact on Human Osteoblasts.” Matrix Biology 112: 1–19. https://doi.org/10.1016/j.matbio.2022.07.005.
Magarinos, N. J., K. J. Bryant, A. J. Fosang, R. Adachi, R. L. Stevens, and H. P. McNeil. 2013. “Mast Cell-Restricted, Tetramer-Forming Tryptases Induce Aggrecanolysis in Articular Cartilage by Activating Matrix Metalloproteinase-3 and -13 Zymogens.” Journal of Immunology 191 (3): 1404–12. https://doi.org/10.4049/jimmunol.1300856.
Martin, A. 2019. “An Acquired or Heritable Connective Tissue Disorder? A Review of Hypermobile Ehlers Danlos Syndrome.” European Journal of Medical Genetics 62 (7): 103672. https://doi.org/10.1016/j.ejmg.2019.103672.
Matheny, M. V., T. Craig, and T. Al-Shaikhly. 2025. “Systematic Review of Omalizumab for Refractory Clonal and Non-Clonal Mast Cell Activation Syndrome.” Allergy and Asthma Proceedings 46 (1): 11–18. https://doi.org/10.2500/aap.2025.46.240076.
Saarinen, J., N. Kalkkinen, H. G. Welgus, and P. T. Kovanen. 1994. “Activation of Human Interstitial Procollagenase Through Direct Cleavage of the Leu83-Thr84 Bond by Mast Cell Chymase.” Journal of Biological Chemistry 269 (27): 18134–40.
Weiss, N., I. Elijah, R. Dahiya, S. Menton, L. Ishmael, and A. Rutt. 2026. “Iatrogenic Subglottic Stenosis in Mast Cell Activation Syndrome: A Sentinel Case and Narrative Review.” Ear, Nose, and Throat Journal. https://doi.org/10.1177/01455613261423415.
Wilson, F. C., D. J. Zangerle, L. E. Rozen, J. J. Fliess, A. A. Darakjian, K. A. Sacco, C. Hamilton, et al. 2026. “Mast Cell Score Associates with Wide-Spread Mast Cell Symptoms and Comorbidities in Patients with hEDS and HSD.” medRxiv [Preprint]. https://doi.org/10.64898/2026.05.31.26354552.
Zhu, J., D. Sun, G. Zeng, K. Wu, X. Yang, X. Zhu, D. Aierken, et al. 2026. “Histaminylation Alters Collagen Matrix Mechanics and Attenuates Cardiac Fibrosis Post-Myocardial Infarction via Mechanotransduction Signaling Axis.” Signal Transduction and Targeted Therapy 11 (1): 229. https://doi.org/10.1038/s41392-026-02721-5.